Browse News
Filter News
Found 485 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Experts are hopeful that objective biomarker measures for amyotrophic lateral sclerosis, such as the ones being developed by EverythingALS, will lead to more targeted, effective treatments.
-
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
4/10/2024
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.
-
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer
4/1/2024
Gain Therapeutics, Inc. today announces the appointment of Jonas Hannestad, M.D., Ph.D. as its chief medical officer, effective as of March 25, 2024.
-
Indivi to Collaborate with Biogen to Advance Digital Health Technology and Digital Biomarkers for Parkinson's Disease
3/26/2024
Indivi, a leading MedTech company headquartered in Basel, Switzerland, has entered into an agreement with Biogen to advance digital health technology and develop digital biomarkers for Parkinson's disease.
-
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
3/21/2024
Alpine Immune Sciences, Inc. announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024.
-
Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology
3/20/2024
Nicox SA announced that the results from the Mont Blanc pivotal Phase 3 trial comparing NCX 470 to latanoprost in the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension have been published in the peer-reviewed journal American Journal of Ophthalmology.
-
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
3/18/2024
AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.* Expanding the savings programs will help make its inhalers more affordable to the most vulnerable patients living with asthma and chronic obstructive pulmonary disease, including those who are uninsured and underinsured.
-
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
3/18/2024
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported full year 2023 financial results and company highlights for the fourth quarter ended December 31, 2023.
-
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024
3/13/2024
Nicox SA, an international ophthalmology company, provided an update on its corporate and development strategy, in the context of its debt restructuring and the appointment of Gavin Spencer as Chief Executive Officer and announced it will be holding a Webcast on March 18, 2024 at 6:00 pm CET.
-
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting
3/5/2024
Nicox SA, an international ophthalmology company, provided details of poster presentations highlighting data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting, one of the key scientific events in vision research, which was held on February 29th to March 3rd, 2024 in Huntington Beach, CA, United States.
-
Amid the limitations of current therapies for amyotrophic lateral sclerosis, a new GlobalData report points to novel disease-modifying drug approaches that could transform the space.
-
Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial
2/28/2024
Nicox SA, an international ophthalmology company, announced that it has signed an agreement in principle to amend its debt agreements with funds and accounts managed by BlackRock, Inc. and its affiliates.
-
Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO
2/28/2024
Nicox SA, an international ophthalmology company, announced its Board of Directors has appointed the highly experienced biotech executive Gavin Spencer as Chief Executive Officer.
-
On the heels of layoffs, Denali Therapeutics has entered into a securities purchase agreement with existing accredited investors as it spins off preclinical small molecule portfolio.
-
Denali Therapeutics Announces $500 million Private Placement Equity Financing
2/27/2024
Denali Therapeutics Inc. today announced that the company has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its common stock at a price of $17.07 per share.
-
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
2/27/2024
Denali Therapeutics Inc. today reported financial results for the fourth quarter and year ended December 31, 2023, and provided business highlights.
-
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates
2/27/2024
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the year ended December 31, 2023, and highlighted recent corporate accomplishments.
-
Representing Denali Therapeutics, I recently participated in a workshop that brought together FDA representatives, patient advocates, academic physicians and scientists and industry to discuss strategies to speed therapies for patients with rare degenerative illnesses.
-
In a Phase II study, Sanofi and Denali’s RIPK1 inhibitor SAR443820/DNL788 failed to meet the primary endpoint of improved functional performance in amyotrophic lateral sclerosis patients.